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proliferation that contributes to the progressivity of 
RA.1-7
Methotrexate is known to trigger liver 
dysfunction as side effect. Liver function is 
evaluated based on alanine aminotransferase (ALT) 
and/or aspartate aminotransferase (AST)  serum 
titer. Elevation of liver enzyme above the upper 
limit indicates liver dysfunction. Based on study in 
India on 30 patients who were treated with MTX 
for 3 months, there was 25% elevation of AST 
above normal range.8 Study in Israel on 119 patients 
who were treated with MTX showed 43% of RA 
patients have abnormal liver enzyme titer.9 Study 
in Iran on 286 patients who were treated with MTX 
found that 23.7% of patients have experienced liver 
dysfunction.10 Based on the previous studies, factors 
that suspected association with liver dysfuction 
are gender, age, MTX cumulative dose, and MTX 
duration therapy.8-11
There is not any study about proportion of liver 
dysfuction on RA patients who are treated with 
MTX in Indonesia. The purpose of this study is to 
have the proportion of liver dysfunction in patients 
who are treated with MTX, and to analyze the 
association between age, gender, MTX cumulative 
dose, MTX therapy duration with liver dysfunction 
incidence, so that clinicians will be more aware 
with MTX use in patients.
Method
This study is a descriptive-analytic study with 
cross-sectional method. From the sample 
population, AST and ALT lab results, age, gender, 
MTX cumulative dose, and MTX duration therapy 
were obtained. The study was conducted in RSUPN 
Dr Cipto Mangunkusumo (RSCM) and RSCM 
Kencana, Jakarta for 11 months, from January to 
November 2016. 
Data were obtained from patients’ medical 
records unit RSCM and RSCM Kencana, which 
meet inclusion criteria and opposite of exclusion 
criteria. The inclusion criterias are patients who 
fulfill diagnosis criteria of based on ACR/EULAR 
2010, received MTX therapy for minimum period 
of one month, and patients of RSCM and RSCM 
Kencana. The exclusion criterias are patients who 
have other comorbidities that can cause liver 
dysfunction.
Abstract
Background: Rheumatoid arhtirtis (RA) is a chronic 
autoimmune disease that mainly attacks joints. 
It may causes joint deformities which leads to 
lower quality of life of RA patients. RA is treated 
with metothrexate (MTX) which inhibiting disease 
progression. MTX is known for its hepatotoxicity side 
effect, which is described by an elevation of aspartate 
aminotransferase (AST) and/or alanine aminotransferase 
(ALT) beyond the upper normal limit. Factors that may 
enhance hepatotoxicity are gender, age, cummulative 
dose of MTX, and duration therapy of MTX. Prevalence 
of hepatotoxicity caused by MTX therapy in RA patients 
in Indonesia is still unknown. The objective of this 
research is to know the proportion of hepatotoxicity 
and its associations with the factors that may enhance 
hepatotoxicity caused by MTX therapy in RA patients in 
RSCM. 
Method: Data about gender, age, cummulative dose 
and duration therapy of MTX are obtained from 115 RA 
patients’ medical records. 
Result: Proportion of hepatotoxicity in RA patients 
treated with MTX in RSCM is 42.60%. Gender, age, 
cummulative dose and duration therapy of MTX do not 
significantly enhance hepatotoxicity (p>0.05).
Conclusion: In conclusion gender, age, cummulative 
dose and duration therapy of MTX do not have 
association with hepatotoxicity in RA patients treated 
with MTX.
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Introduction
Rheumatoid arthritis (RA) is an inflammatory 
disease which has large impacts on daily activities 
of its sufferers. Inflammation manifests as pain 
that causes joint immobility. American College 
of Rheumatology and European Leauge Against 
Rheumatism (ACR-EULAR) created a tool to help 
diagnose RA in 2010. After the diagnosis is set, 
patient would be treated with Disease Modifying 
Anti Rheumatic Drugs (DMRADs). The target 
of DMARDs therapy is inhibiting joint erosion 
and causing remission. Based on ACR guideline 
on management of RA in year 2015, the first line 
therapy for is methotrexate (MTX). MTX works 
by supressing cytokine release and lymphocyte 
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Data were processed by SPSS software and analyzed with 
inferential statistic. Gender and liver function variables were 
analyzed with Fisher test. Age, MTX cumulative dose, and 
MTX therapy duration variables undergone sample normality 
test with Kolmogorov Smirnov test. If the data distribution 
were normal, unpaired T- test between age, MTX cumulative 
dose, and MTX duration therapy and liver function would 
be conducted. If not normal, the Mann-Whitney test would 
be done. From the Mann-Whitney test, p value showed data 
significance.
Result
From 115 samples who were obtained, all the samples were 
given MTX with minimum dosage of 7.5 mg each week for 
minimum duration of one month. Samples do not have any 
comorbidities that could result in liver dysfunction. Samples 
demographic datas are shown in Table 1.
Table 1. Samples Demographic Data
Variable  Result
Gender, frequency (%)
Men
Women
9 (7.83%)
106 (92.17%)
Age (year) 53.55	(19.98−84.53)*
MTX cumulative dose (mg) 480.00	(25.00−3967.50)*
MTX duration therapy (week) 44.00	(4−226)*
AST titer, frequency (%)
Normal
1−2	times	above	normal
>2 times above normal
73 (63.48%)
36 (31.30%)
6 (5.22%)
ALT titer, frequency (%)
Normal
1−2	times	above	normal	
>2 times above normal
75 (65.22%)
34 (29.56%)
6 (5.22%)
Liver dysfunction, frequency (%) 49 (42.60%)
*:not	normally	distributed	data,	data	presented	in	median	(range)
Association between gender and liver dysfunction
There is no significant difference between proportion of men and 
women (p>0.05) in group with liver dysfunction and without.
Table 2. Association between gender and liver dysfunction
Variables Normal LFT Disturbed LFT P value
Women 63 (95.5)
3 (4.5)
43 (87.8)
6 (12.2)
0.167
Men
LFT: Liver Function Test
Association between age and liver dysfunction
There is no significant association between age and liver 
dysfunction incidences (p>0.05). 
Table 3.  Association between age and liver dysfunction
Liver function Result P score
Age
Normal 52.85	(19.98−84.53)*
0.46−0.23
Disturbed 54.78	(23.56−72.75)*
*:not normally distributed data, data presented in median (range)
Association between MTX cumulative dose and liver dysfunction
There is no significant association between MTX cumulative 
dose and liver dysfunction incidences (p>0.05). 
Table 4. Association between MTX cumulative dose and liver 
dysfunction 
Liver
function Result P score
MTX 
cumulative 
dose
Normal 378.75	(25.00−3337.50)*
0.23−0.115Disturbed 495.00	(50.00−3967.50)*
*:not	normally	distributed	data,	data	presented	in	median	(range)
Association between MTX duration therapy and liver dysfunction
There is no significant association between MTX duration 
therapy and liver dysfunction incidences (p>0.05). 
Table 5. Association between MTX duration and liver dysfunction
 Liver function Result P score
MTX 
duration 
therapy
Normal 43	(4−226)	*
0.519−0.259
Disturbed 44	(5−207)	*
*:not	normally	distributed	data,	data	presented	in	median	(range)
Discussion
Proportion of liver dysfuction in patients who are treated 
with MTX in RSCM and RSCM Kencana is 42.60%. The 
proportion of liver dysfunction in this study is higher than 
study conducted by Sotoudenamesh et al which has proportion 
of liver dysfunction 23.7%.11 However, proportion of liver 
dysfunction in this study is suitable with other studies which 
conducted by Ede et al which stated that proportion of liver 
dysfunction is 53% and Bath et al which stated proportion 
of liver dysfunction is 15−50%. RA patients who are treated 
with chronic MTX experienced elevations in ALT and/or AST 
above the normal upper limit. About 5% of which experienced 
elevation until 2 times the normal range.12 This study result 
has 5.22% samples who experienced AST and/or ALT 2 
times normal range. In the literature review by Conway et al 
liver dysfunction incidence is higher than liver dysfunction 
incidence in this study, AST and/or ALT elevations above 
normal upper limit and those who elevated above two times 
normal range is 48.9% and 16.8% respectively.13
Variations of liver dysfunction proportion in other studies 
might be caused different definitions of liver dysfunction. In 
this study, liver dysfunction is described as ALT and or AST 
abnormal result while treated with MTX. Sotoudenamesh 
et al described liver dysfunction as two abnormal ALT 
and AST results in interval of 2 weeks.10 Kremer et al 
described liver dysfunction based on liver hystology. The 
proportion differences also can be caused by different sample 
characteristics (ethnic and genetic variation).10
The time of laboratory test from last administration of 
MTX can also affect the liver enzyme titer. If the lab test were 
conducted after MTX administration, liver enzyme titer would 
be higher.14
Folic acid supplementation is known to decrease the 
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frequency of liver enzyme elevation.15 MTX hepatotoxicity 
mechanism is still unknown but allegedly result from the same 
mechanism of this drug mechanism of action. MTX causes 
inhibition of DNA and RNA synthesis in liver which result 
in damage and degeneration of liver cell. If the patients were 
given folic acid, DNA and RNA synthesis are not disturbed.14, 16 
Epidemiologically, RA incidence is two to three times 
higher in women than in men. The reason behind it is still 
unknown but thought to be genetic factor that X linked and 
estrogen factor.14 Studies by Amital et al and Parvin et al 
found women are more fragile to liver enzyme elevations.8,9 
Hoekstra et al study shown women are more prone to MTX 
treatment discontinuation.15 However, in this study, gender 
and liver dysfunctions do not have any significant association. 
This study result is suitable to Sotoudenamesh et al study.10
Age median in this study is 52.8 years (19.98, 84.53) 
in group without liver dysfunction and 54.78 years (23.56, 
72.75) in group with liver dysfuncton. There is no significant 
association between age and liver dysfunction incidence. This 
result is suitable to study by Sotoudenamesh et al, Hoekstra, 
and McKendry which also did not find any association be-
tween age and liver dysfunction in RA patients who are treated 
with MTX.10,15
Most of MTX would be eleminated from the body through 
kidney, meanwhile kidney function would degenerate as the 
age increased. If MTX titer in body high, the risk of hepato-
toxicity is even higher. Therefore age is considered as risk fac-
tor for MTX hepatotoxicity. However, some studies showed 
different result from the theory. Study by Felson in 496 RA 
patients and Bologna in 469 RA patients did not find asso-
ciation between age, kidney function, and elevation of liver 
enzymes.15 In this study, the researchers do not know about 
patients’ kidney function.
In this study, there is no significant comparison between 
MTX cumulative dose in group with liver dysfunction and 
without liver dysfunction. MTX cumulative dose median in 
group with liver dysfunction is 495 mg, meanwhile in group 
without liver dysfunction is 378.75 mg. Even though there is 
no significant difference, MTX cumulative dose median in 
group with liver dysfunction is higher than cumulative dose 
median in group without liver dysfunction. In this study, MTX 
cumulative dose is lower than in other previous studies. 
The result of this study is not suitable with studies which 
conducted by Sakthiswary et al and Sotoudenamesh et al 
which were acquired significant difference of MTX cumula-
tive dose in group with liver dysfunction and without liver 
dysfunction.10,17  According to the theory, incidences of hepa-
totoxicity are associated with increasing MTX dose. However, 
in various studies by West et al and Lanse et al also did not 
find any increasing risk of hepatotoxicity with increasing of 
MTX dose.18
Study by Bath et al showed significant association between 
MTX cumulative dose and liver dysfunction in RA patients 
treated with MTX once a day or every two days. However, in 
RA patients treated with MTX once a week, there is a weak 
association between MTX cumulative dose and hepatotoxic-
ity. Liver dysfunction incidence is more associated with time 
interval between two MTX administrations than MTX cu-
mulative dose. When the drug is administrated in one week 
interval, MTX titer in the body is not high enough to cause 
hepatotoxicity.18 In this study, RA patients are treated with 
MTX weekly. No significant difference in MTX cumulative 
dose and liver dysfunction could be caused by time interval 
between two administrations. Studies by Parvin et al and Rau 
et al stated that liver enzymes elevations were transient and 
will normalized after decreasing of MTX dose, giving of  folic 
acid, or even without changes in MTX dose. 8,19
No significant difference between MTX cumulative dose 
and liver dysfunction incidence could be caused by MTX cu-
mulative dose which are lower in this study than other previ-
ous studies. In this study, MTX cumulative dose median in 
group without liver dysfunction is 378.75 mg and group with 
liver dysfunction is 495 mg. Meanwhile in Sotoudenamesh et 
al, MTX cumulative dose mean in group without liver dys-
functon is 1707.3 mg with 45.2% of them were given MTX 
more than 1.5 g.10 In the literature review by Kremer, hepato-
toxicity incidence in RA patients who are treated with MTX is 
low. Hepatotoxicity incidence is higher in cancer patients who 
are treated with higher MTX dose.8
The median MTX duration therapy in group with liver 
dysfunction is 43 weeks and without liver dysfunction is 44 
weeks. In this study, there is no significant association between 
MTX duration therapy and liver dysfunction. This result could 
be caused by short MTX duration therapy. Sotoudenamesh et 
al studies found significant association between MTX dura-
tion therapy and liver dysfunction. In  Sotoudenamesh et al 
study, MTX duration therapy in group with liver dysfunction 
reached 59.6±42.3 months.10
MTX duration therapy is associated with MTX cumula-
tive dose. However, hepatotoxicity is more associated with 
time interval between two drug administrations than the MTX 
duration therapy. In study by Rau et al, hepatotoxicity is not 
a significant side effect in weekly low dose MTX therapy. Pa-
tients are more tolerant with weekly MTX therapy than daily 
MTX therapy.
Conclusion
Based on this study, it could be concluded proportion of RA 
patients who have liver dysfunction caused by MTX therapy 
in RSCM is 42.70%. Gender, age, MTX cumulative dose, and 
MTX duration therapy do not have any statistically significant 
association with liver dysfunction. 
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